NXL

$1.57+0.64%visit website

Nexalin Technology, Inc.

Market Cap

$35M

Live price × SEC shares (Aug 10, 2026)

Sector

Health Care

Industry

Health Care

Beta (raw)

4.28

49mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

159.3

TTM to Jun 2026 · revenue

P/B

22.8

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	18	172	15	12	217
Cost of revenue	3.9	21.0	1.8	3.3	30.1
Gross profit	14	151	13	9	187
Research & development	227	225	346	564	1,362
Selling, general & administrative	1,420	1,155	793	783	4,151
Total operating expenses	2,360	2,564	2,133	2,256	9,313
Operating income	(2,346)	(2,413)	(2,120)	(2,247)	(9,126)
Interest expense	(2.29)	(0.16)	(0.03)	(0.13)	(2.61)
Pretax income	(2,276)	(2,377)	(2,097)	(2,239)	(8,989)
Net income	(2,276)	(2,377)	(2,097)	(2,239)	(8,989)
EPS (basic) ($)	(0.13)		(0.11)	(0.11)	—
EPS (diluted) ($)	(0.13)		(0.11)	(0.11)	—
Weighted avg. shares (basic)	17,794		19,821	21,143
Weighted avg. shares (diluted)	17,794		19,821	21,143

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 12, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 16 more quarters, back to Sep 2021, with Tormere Pro.